<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644239</url>
  </required_header>
  <id_info>
    <org_study_id>Faculdade de Saúde Pública USP</org_study_id>
    <nct_id>NCT02644239</nct_id>
  </id_info>
  <brief_title>Impact of Ketogenic Diet on Lipoproteins in Refractory Epilepsy</brief_title>
  <acronym>Ketonutri</acronym>
  <official_title>Classic Ketogenic Diet and Modified: Evaluation of the Therapeutic Potential and Impact on the Oxidative Profile, Lipidomic, Inflammatory and Size of Lipoproteins in Children and Adolescents With Refractory Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ketogenic diet is a non-pharmacological treatment prescribed especially for children and
      indicated in most specialized centers for patients with refractory epilepsy. The composition
      of the ketogenic diet is based on high-fat, low-carbohydrate, moderate protein content, and
      the production of ketone bodies is the probable mechanism involved in the control of
      seizures. The relationship between the treatment of the ketogenic diet and changes in
      oxidative characteristics, physical and lipid are not well established. Some studies show a
      significant increase in total cholesterol and triglycerides in children being treated with
      ketogenic diet, but other studies have shown that changes in lipid profile in the long term
      do not appear to be significant, beyond the influence of these changes on coronary heart
      disease are unknown. The studies performed in the last two decades have shown that besides
      the changes in the lipid profile, oxidative modification of lipoproteins are essential for
      the initiation and progression of atherosclerosis and physical properties of lipoproteins
      also appear to be involved in this process, suggesting that the particle size of
      lipoproteins, through the analysis of subfractions can provide more details of the
      cardiovascular risk. Thus, this projetct aims to compare the effects of the classical
      ketogenic diet with the ketogenic diet modified with lower content of saturated fatty acids
      and a higher content of monounsaturated and polyunsaturated, the oxidative changes of LDL,
      lipidomic profile, the concentration of antioxidants in production inflammatory cytokines and
      the subfractions of LDL and HDL in children and adolescents with refractory epilepsy, the
      clinical effect on controlling epilepsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Controlled clinical trial composed of children of adolescents aged 1 to 19 years with
      refractory epilepsy drug polytherapy (antiepileptic drugs). Children of both sexes are being
      included. The control group receive the diet classical ketogenic while the case group receive
      the ketogenic diet modified reduction of at least 20% of the supply of saturated fat and
      increase&gt; 50% of the acid supply monounsaturated fatty, increase&gt; 50% of acid content
      polyunsaturated fatty and a lower ratio w6 / w3 at least 50% compared to classical diet used
      by the control group. Patients are followed in 3 times: baseline, 3 months and 6 months after
      the intervention.

      Exclusion criteria: Children and adolescents who use any type of hormone replacement;
      Children and adolescents who present diagnosis of diabetes mellitus and hypothyroidism or
      hyperthyroidism; Children and adolescents with acute illnesses such as heart disease and
      kidney disease that prevent indication of the DC evaluated by medical history and complete
      physical examination by the neurologist doctor in charge of the clinic.

      Outcome Measures:

      a. Characterize the sample as the demographics (gender, age), scioeconomic, quality of life
      and clinical; B. To assess dietary intake through food records; c. Evaluate the
      anthropometric profile and classify the nutritional status (Z score of body mass index for
      age [ZBMI / I]); d. Assess body composition (percentage of fat, lean mass, total body water
      and phase angle); e. Determine the concentration of cholesterol and triglycerides,
      lipoproteins (TC, TG, LDL and HDL); f. Determine the concentration of apolipoproteins: APOA-1
      and APO-B; g. Detect the concentration of ketone bodies in the plasma (β-hydroxybutyrate); H.
      Detecting LDL (-) and oxidized LDL in plasma; i. To detect anti-LDL autoantibodies (-) and
      anti-oxLDL autoantibodies in plasma; j. Determine subfractions HDL, LDL and high LDL particle
      size; k. To evaluate the concentration of non-esterified fatty acids (NEFAs); l. Assess the
      concentration of fatty acids in plasma; m. To assess the concentration of substances reactive
      to thiobarbituric acid (TBARS) in plasma.

      n. Determine the concentration of antioxidants in plasma: α-tocopherol, beta-carotene and
      retinol.

      O. Determining the lipidomic plasma profile gathering lipid species in more classes
      associated with the risk of cardiovascular disease; P. Detecting inflammatory markers: Tumor
      necrosis factor (TNF-α), interleukin (IL-6) in plasma.

      Q. Determine the concentration of hepatic enzymes R. Determine the leptin, adiponectin,
      ghrelin and resistin S. To evaluate the liver ultrasound and carotid ultrasound
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Socioeconomic and clinical profile</measure>
    <time_frame>average of 3 months</time_frame>
    <description>age, income, disease, parent´s education, use of drugs and supplements, type of seizures, questions about quality of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>average of 3 months</time_frame>
    <description>BMI according growth charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass</measure>
    <time_frame>average of 3 months</time_frame>
    <description>Fat mass by impedance bioeletrical</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat free mass</measure>
    <time_frame>average of 3 months</time_frame>
    <description>fat free mass by impedance bioeletrical</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase angle</measure>
    <time_frame>average of 3 months</time_frame>
    <description>phase angle mass by impedance bioeletrical</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessement of food intake</measure>
    <time_frame>average of 3 months</time_frame>
    <description>Food record applied during 3 days to each time</description>
  </other_outcome>
  <other_outcome>
    <measure>Ketone bodies</measure>
    <time_frame>average of 3 months</time_frame>
    <description>Concentration of B-hydroxybutirate in plasma. Determination with kit Ranbut (Randox Laboratories Limited, Reino Unido).</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid profile</measure>
    <time_frame>average of 3 months</time_frame>
    <description>Total cholesterol, LDL, HDL, TG</description>
  </other_outcome>
  <other_outcome>
    <measure>NEFAS</measure>
    <time_frame>average of 3 months</time_frame>
    <description>Concentration in plasma. Determination with kit NEFAS(Randox Laboratories Limited, Reino Unido)</description>
  </other_outcome>
  <other_outcome>
    <measure>LDL oxidized</measure>
    <time_frame>average of 3 months</time_frame>
    <description>Determination in plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>Antioxidant</measure>
    <time_frame>average of 3 months</time_frame>
    <description>Determination of antioxidant concentration in plasma by HPLC</description>
  </other_outcome>
  <other_outcome>
    <measure>Metabolomic (lipidomic)</measure>
    <time_frame>average of 3 months</time_frame>
    <description>Determination in plasma by mass spectrometry</description>
  </other_outcome>
  <other_outcome>
    <measure>Subfractions of Lipoproteins</measure>
    <time_frame>average of 3 months</time_frame>
    <description>Determination in plasma by Lipoprint</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver enzymes</measure>
    <time_frame>average of 3 months</time_frame>
    <description>Concentration of AST, ALT, GGT</description>
  </other_outcome>
  <other_outcome>
    <measure>Hepatic function</measure>
    <time_frame>average of 3 months</time_frame>
    <description>Ultrasound liver</description>
  </other_outcome>
  <other_outcome>
    <measure>Leptin</measure>
    <time_frame>average of 3 months</time_frame>
    <description>Determination in plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>Resistin</measure>
    <time_frame>average of 3 months</time_frame>
    <description>Determination in plasma</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Epilepsy</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Group control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>classical ketogenic diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group case</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group case: modified ketogenic diet to reduce at least 20% saturated fat, up&gt; 50% of the acid supply monounsaturated, increasing&gt; 50% polyunsaturated fatty acid content and a lower ratio w6 / w3 at least 50% compared to classic diet used by the control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ketogenic diet</intervention_name>
    <description>Ketogenic diet with high fat (90%)</description>
    <arm_group_label>Group control</arm_group_label>
    <arm_group_label>Group case</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Participate in the study children and adolescents of both sexes with
        age 1-19 years diagnosed with refractory epilepsy drug polytherapy ( antiepileptic drugs )
        and indication of treatment with KD .

        Exclusion Criteria: Children and adolescents who use any type of hormonal replacement ;

          -  Children and adolescents who submit diagnosis of diabetes mellitus and hypothyroidism
             or hyperthyroidism ;

          -  Children and adolescents showing acute disorders as heart disease and kidney diseases
             .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariana Baldini Prudencio, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Universidade of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nagila Raquel Teixeira Damasceno, Ph D</last_name>
    <phone>+55(11) 3061-7865</phone>
    <email>nagila@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Azevedo, Ph D Student</last_name>
    <phone>1130617865</phone>
    <email>patricia.azlima@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nagila Raquel Teixeira Damasceno</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01246-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Azevedo, PhD Student</last_name>
      <phone>1130617865</phone>
      <email>patricia.azlima@yahoo.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Avogaro P, Bon GB, Cazzolato G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis. 1988 Jan-Feb;8(1):79-87. Erratum in: Arteriosclerosis 1988 Nov-Dec;8(6):857.</citation>
    <PMID>3341993</PMID>
  </reference>
  <reference>
    <citation>Avogaro P, Cazzolato G, Bittolo-Bon G. Some questions concerning a small, more electronegative LDL circulating in human plasma. Atherosclerosis. 1991 Nov;91(1-2):163-71.</citation>
    <PMID>1811552</PMID>
  </reference>
  <reference>
    <citation>Faulin Tdo E, de Sena-Evangelista KC, Pacheco DB, Augusto EM, Abdalla DS. Development of immunoassays for anti-electronegative LDL autoantibodies and immune complexes. Clin Chim Acta. 2012 Jan 18;413(1-2):291-7. doi: 10.1016/j.cca.2011.10.004. Epub 2011 Oct 18.</citation>
    <PMID>22037508</PMID>
  </reference>
  <reference>
    <citation>Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshé SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014 Apr;55(4):475-82. doi: 10.1111/epi.12550. Epub 2014 Apr 14. Review.</citation>
    <PMID>24730690</PMID>
  </reference>
  <reference>
    <citation>Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, Engel J Jr. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005 Apr;46(4):470-2.</citation>
    <PMID>15816939</PMID>
  </reference>
  <reference>
    <citation>Freeman JM, Kossoff EH, Hartman AL. The ketogenic diet: one decade later. Pediatrics. 2007 Mar;119(3):535-43. Review.</citation>
    <PMID>17332207</PMID>
  </reference>
  <reference>
    <citation>Kossoff EH, Zupec-Kania BA, Amark PE, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, Buchhalter JR, Caraballo RH, Helen Cross J, Dahlin MG, Donner EJ, Klepper J, Jehle RS, Kim HD, Christiana Liu YM, Nation J, Nordli DR Jr, Pfeifer HH, Rho JM, Stafstrom CE, Thiele EA, Turner Z, Wirrell EC, Wheless JW, Veggiotti P, Vining EP; Charlie Foundation, Practice Committee of the Child Neurology Society; Practice Committee of the Child Neurology Society; International Ketogenic Diet Study Group. Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. Epilepsia. 2009 Feb;50(2):304-17. doi: 10.1111/j.1528-1167.2008.01765.x. Epub 2008 Sep 23.</citation>
    <PMID>18823325</PMID>
  </reference>
  <reference>
    <citation>Kwiterovich PO Jr, Vining EP, Pyzik P, Skolasky R Jr, Freeman JM. Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children. JAMA. 2003 Aug 20;290(7):912-20.</citation>
    <PMID>12928468</PMID>
  </reference>
  <reference>
    <citation>Lee PR, Kossoff EH. Dietary treatments for epilepsy: management guidelines for the general practitioner. Epilepsy Behav. 2011 Jun;21(2):115-21. doi: 10.1016/j.yebeh.2011.03.008. Epub 2011 Apr 21. Review.</citation>
    <PMID>21514240</PMID>
  </reference>
  <reference>
    <citation>Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009 Dec 1;54(23):2129-38. doi: 10.1016/j.jacc.2009.09.009. Review.</citation>
    <PMID>19942084</PMID>
  </reference>
  <reference>
    <citation>Liu YM, Williams S, Basualdo-Hammond C, Stephens D, Curtis R. A prospective study: growth and nutritional status of children treated with the ketogenic diet. J Am Diet Assoc. 2003 Jun;103(6):707-12.</citation>
    <PMID>12778041</PMID>
  </reference>
  <reference>
    <citation>WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr Suppl. 2006 Apr;450:76-85.</citation>
    <PMID>16817681</PMID>
  </reference>
  <reference>
    <citation>de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ. 2007 Sep;85(9):660-7.</citation>
    <PMID>18026621</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Patricia Azevedo de Lima</investigator_full_name>
    <investigator_title>Ph.D. Student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

